Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.
Postoperative nausea and vomiting (PONV) affects roughly 25 to 30% of surgical patients, and although the condition is rarely life-threatening, it remains a significant source of patient distress, delayed recovery, and unplanned hospital admission (Kovac, 2000). Some patients, estimated at 0.18% of all surgical cases, experience intractable PONV despite standard prophylaxis and first-line interventions (Kovac, 2000). In addition to severe discomfort and distress, intractable postoperative nausea and vomiting (PONV) can result in complications involving dehydration, electrolyte imbalance, and injury to surgical wounds.
The strategy for managing intractable PONV differs from that of prevention. Because emetic signaling involves multiple midbrain receptor systems, including dopaminergic, muscarinic, histaminergic, opioid, and serotonergic pathways at the chemoreceptor trigger zone, area postrema, and nucleus of the solitary tract, no single agent reliably controls symptoms in every patient (Kovac, 2000).
When a patient vomits repeatedly despite an initial antiemetic, the evidence consistently supports switching to or adding an agent that acts at a different receptor site rather than repeating or escalating the same drug class. A multicenter trial of repeat-dose intravenous ondansetron 4 mg found that a second dose offered no additional benefit once initial prophylaxis had failed, reinforcing the principle that receptor-site redundancy, not underdosing, is usually the problem (Kovac, 2000).
Among rescue agents, the 5-HT3 receptor antagonists (ondansetron, granisetron, tropisetron, dolasetron) remain the most extensively studied. A quantitative systematic review of placebo-controlled treatment trials found that these drugs produce an absolute risk reduction of roughly 20% to 30% in further vomiting among patients already experiencing symptoms, with weaker and less consistent effects on nausea itself (Kazemi-Kjellberg et al., 2001).
Notably, this analysis found little evidence of a clinically meaningful dose-response relationship across wide dose ranges, indicating that minimal effective doses can reasonably be used for treatment even though considerably higher doses are typically chosen for prophylaxis (Kazemi-Kjellberg et al., 2001). Headache was the most consistent adverse effect and showed a dose-dependent trend, providing further support for using the lowest effective rescue dose (Kazemi-Kjellberg et al., 2001).
Combination therapy has the strongest evidence base for treating difficult cases. Adding dexamethasone to a 5-HT3 antagonist produces a further reduction in PONV beyond either agent alone, with the benefit being most pronounced for late (up to 24-hour) symptoms (Henziet al., 2000). Dexamethasone’s relatively long biological half-life of 36 to 72 hours may explain this delayed but sustained effect (Henzi et al., 2000). Reported adverse effects with dexamethasone were uncommon in these trials, though most excluded patients with diabetes, corticosteroid dependence, or immunosuppression; therefore, caution is still warranted in those populations (Henzi et al., 2000).
For patients whose PONV continues despite combination pharmacotherapy, a broader multimodal strategy is advisable. This includes minimizing further exposure to medications associated with PONV, such as opioids, ensuring adequate intravenous hydration to correct orthostatic contributors, treating unaddressed pain, and considering P6 acupressure or transcutaneous acupoint stimulation as adjuncts, both of which have shown modest but reproducible benefit in prospective trials (Kovac, 2000). Multimodal clinical algorithms combining total intravenous anesthesia, avoidance of nitrous oxide, aggressive hydration, and triple antiemetic therapy have demonstrated superior control of symptomatic PONV compared with routine monotherapy prophylaxis (Kovac, 2000).
Ultimately, intractable PONV should prompt reassessment of the full risk profile, including patient-, anesthesia-, and surgery-related factors, rather than simple repetition of the initial regimen. Layering antiemetics across distinct receptor systems, administering dexamethasone early due to its delayed onset, and reserving nonpharmacological adjuncts for refractory cases represent the most evidence-based approach currently available.
References
- Henzi, I., Walder, B., & Tramèr, M. R. (2000). Dexamethasone for the prevention of postoperative nausea and vomiting: A quantitative systematic review. Anesthesia & Analgesia, 90(1), 186–194. https://doi.org/10.1097/00000539-200001000-00038
- Kazemi-Kjellberg, F., Henzi, I., & Tramèr, M. R. (2001). Treatment of established postoperative nausea and vomiting: A quantitative systematic review. BMC Anesthesiology, 1, 2. https://doi.org/10.1186/1471-2253-1-2
- Kovac, A. L. (2000). Prevention and treatment of postoperative nausea and vomiting. Drugs, 59(2), 213–243. https://doi.org/10.2165/00003495-200059020-00005